• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Budesonide triple therapy significantly lowers exacerbation rates in severe COPD

byHarsh ShahandDeepti Shroff Karhade
June 25, 2020
in Emergency, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Triple therapy for severe chronic obstructive pulmonary disease (COPD) with budesonide-glycopyrrolate-formoterol was associated with significantly lower risk of COPD exacerbation compared to dual therapy groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Treatment for COPD involves a stepwise approach where treatments are added when necessary to control symptoms and reduce exacerbations. Triple therapy includes an inhaled glucocorticoid, a long-action muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA). Tripe therapy is recommended for patients continually experiencing exacerbations from dual therapy of LAMA-LABA or inhaled glucocorticoid-LABA. As such, this study compared the efficacy and safety of the triple therapy of budesonide-glycopyrrolate-formoterol combination and two dual therapies, glycopyrrolate-formoterol (LAMA-LABA) and budesonide-formoterol (inhaled glucocorticoid-LABA). The study determined that patients in the triple therapy group had lower rates of exacerbations compared to the patients in the two dual therapy groups. One limitation of this randomized trial was the higher incidence of pneumonia within the patient population compared to previously published randomized control trials regarding COPD therapies. Nonetheless, this study was strengthened by the long-term patient follow-up between the treatment groups.

Click to read the study in NEJM

Relevant Reading: Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

In-Depth [randomized controlled trial]: This randomized control trial enrolled 8588 patients in a multicenter study from 25 countries. The study included patients between 40 to 80 years of age, who received at least two inhaled maintenance therapies and had symptomatic COPD. The exclusion criteria for the study included current diagnosis of asthma. The patients were randomized in a 1:1:1:1 ratio to receive 160ÎĽg- budesonide triple therapy dose, 320ÎĽg- budesonide triple therapy dose, glycopyrrolate-formoterol, or budesonide-formoterol. The primary outcome was the annual rate of moderate to severe COPD exacerbations. Moderate exacerbation was defined as leading to systemic glucocorticoid and/or antibiotic treatment for at least three days. Severe exacerbation was defined as resulting in hospitalization or death. The annual rate for exacerbations was significantly lower with 320ÎĽg- budesonide triple therapy dose compared to glycopyrrolate-formoterol (rate ratio, 0.76; 95% confidence interval [CI], 0.69 to 0.83, P<0.0001) and budesonide-formoterol (rate ratio, 0.87; 95% CI, 0.79 to 0.95; P=0.003). Furthermore, no difference was observed between the two triple therapies (rate ratio: 1.00, 95% CI, 0.91 to 1.10). Finally, the risk of death from any cause in the 320ÎĽg triple therapy group was 46% lower than the glycopyrrolate-formoterol group (hazard ratio, 0.54; 95% CI, 0.34 to 0.87) and 22% lower than the budesonide-formoterol group (hazard ratio, 0.78; 95% CI, 0.47 to 1.30). Taken together, administration of triple therapy of budesonide-glycopyrrolate-formoterol significantly lowered rates of exacerbations in patients with moderate or severe COPD.

Image: PD

RELATED REPORTS

Albuterol-budesonide combination efficacious for asthma exacerbation rescue

Inhaled budesonide shortens time to recovery for high-risk COVID-19 patients in the community

Use of inhaled corticosteroids is not associated with improved COVID-related mortality in patients with chronic respiratory conditions

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: budesonidechronic obstructive pulmonary disease (COPD)COPD exacerbationformoterol
Previous Post

Kidney function in type 1 diabetes does not benefit from allopurinol therapy

Next Post

Modestly lower carbohydrate diet not associated with improved outcomes related to gestational diabetes

RelatedReports

Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Emergency

Albuterol-budesonide combination efficacious for asthma exacerbation rescue

June 21, 2022
Microbe-rich environment associated with lower rates of asthma
Infectious Disease

Inhaled budesonide shortens time to recovery for high-risk COVID-19 patients in the community

September 14, 2021
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Infectious Disease

Use of inhaled corticosteroids is not associated with improved COVID-related mortality in patients with chronic respiratory conditions

December 27, 2020
#VisualAbstract: Metoprolol for the Prevention of Acute Exacerbations of COPD
StudyGraphics

#VisualAbstract: Metoprolol for the Prevention of Acute Exacerbations of COPD

November 18, 2019
Next Post
Dietary variety linked to greater increase in childhood BMI

Modestly lower carbohydrate diet not associated with improved outcomes related to gestational diabetes

#VisualAbstract: Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

#VisualAbstract: Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant

Hydroxychloroquine ineffective as post-exposure prophylaxis for Covid-19

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Management of uncomplicated urinary tract infections amongst women in the United States Military Health System highly concordant with guidelines
  • Gout flares associated with a transient increase in subsequent risk of cardiovascular events
  • Litifilimab associated with reduced disease severity in patients with cutaneous lupus erythematosus
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.